Dr Lalchandani Labs Ltd

Dr Lalchandani Labs Ltd announced the approval of its audited standalone financial results for the fiscal year ended March 31, 2026. The Board of Directors, in a meeting held on June 3, 2026, also appointed M/s. Brickwork Ratings India Private Limited as the new Monitoring Agency for the utilization of Rights Issue Proceeds, replacing M/s. Infomerics Valuation and Ratings Limited. The company reported a waiver of Rs. 61.08 lacs under an One Time Settlement (OTS) scheme for its unsecured loans. The financial statements indicate total assets of Rs. 1,760.05 Lacs and total equity and liabilities of Rs. 1,760.08 Lacs as of March 31, 2026. The company also provided cash flow statements, showing net cash flow from operating activities at (₹76.46) Lacs and from investing activities at (₹50.94) Lacs, while financing activities generated ₹211.74 Lacs.

Dr Lalchandani Labs Ltd announced the approval of its audited standalone financial results for the half-year and full year ended March 31, 2026. The Board of Directors also approved the appointment of M/s. Brickwork Ratings India Private Limited as the new Monitoring Agency for the utilization of Rights Issue Proceeds, replacing M/s. Infomerics Valuation and Ratings Limited. The company reported a net profit before tax adjustment of ₹76.46 Lacs from operating activities and a net cash flow from financing activities of ₹211.74 Lacs, resulting in an increase in cash and cash equivalents to ₹414.08 Lacs.

Dr Lalchandani Labs Ltd has postponed its board meeting, originally scheduled for May 30, 2026, to June 3, 2026. The meeting was intended to consider and approve the audited financial results for the half year and year ended March 31, 2026. The postponement is due to an ongoing internal review of certain financial and operational data related to the financial statements. The company management decided to complete the review before presenting the statements to the board.

Dr. Lalchandani Labs Limited has successfully opened a new Strategic Centre at Vardhman Star City Mall, Dwarka, New Delhi. This expansion is a significant milestone in the company's growth strategy, reinforcing its commitment to strengthening its presence across key geographic markets. The new center is strategically located to cater to the large Government employee population in Dwarka and surrounding areas, and aims to expand the company's reach in the Dwarka and Palam belt, regions where it historically had limited business. The company anticipates the new center will generate approximately ₹1 Crore per annum, contributing positively to overall growth and market penetration. Managing Director, Sh. Arjan Lalchandani, highlighted its importance in expanding the company's footprint in high-potential markets and enhancing customer service in West Delhi.

Dr Lalchandani Labs Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited financial results for the half year and year ended March 31, 2026. In compliance with SEBI regulations, the trading window will remain closed until 48 hours after the declaration of these financial results.

Dr Lalchandani Labs Ltd responded to a clarification sought by the exchange dated April 13, 2026, regarding significant share price movement. The company stated that there is no pending price-sensitive information or announcement that could have caused such movement. It clarified that the share price fluctuation is entirely market-driven and affirmed its commitment to duly inform the stock exchange of all required disclosures under SEBI (LODR) Regulations, 2015.

In compliance with BSE Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019, and the Securities & Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the securities of Dr Lalchandani Labs Ltd will be closed for all Directors, Promoters, Designated Persons, Immediate relatives and other Connected Persons as per SEBI regulations from Wednesday, April 01, 2026. The Trading Window will reopen 48 hours after the declaration of audited financial results of the Company for the year ended March 31, 2026. The date of the Board Meeting to consider the Audited Financial Results of the Company for the year ended March 31, 2026 will be informed separately.

According to a disclosure made under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, Anuraag Gambhir has acquired 13,00,000 equity shares in Dr Lalchandani Labs Ltd. The acquisition took place on March 02, 2026, under the Right issue allotment. The total equity share capital of the company before the acquisition was Rs. 4,33,30,680, which increased to Rs. 8,63,70,680 after the acquisition. The total diluted share/voting capital of the TC after the said acquisition is not available.

Dr Lalchandani Labs Ltd has approved the allotment of 43,04,000 (Forty-Three Lakhs Four Thousand) fully paid-up equity shares of the face value of *10 each, following the Rights Issue that opened on February 04, 2026, and closed on February 27, 2026. The allotment is at an issue price of Rs. 10/- per equity share. The Board of Directors also approved the increase in the paid-up equity share capital of the Company to Rs. 8,63,70,680 (8 Crores 63 Lakhs 70 Thousand 680 Only).

Dr Lalchandani Labs Ltd conducted a board meeting on March 02, 2026, to approve the basis of allotment for the rights issue of 43,04,000 fully paid-up equity shares. The rights issue, which opened on February 04, 2026, and closed on February 27, 2026, was priced at Rs. 10 per equity share. The board approved the allotment of the shares to eligible shareholders and/or renouncees. This decision will increase the company's paid-up equity share capital from Rs. 4,33,30,680 to Rs. 8,63,70,680.